Latest From Daniel Chancellor
The success of a drug depends on investment and lifecycle management. Keytruda is the most valuable drug in the industry, while trendy GLP-1 agonists are a prominent drug class.
The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.
The long-term success of TechBio is dependent upon the flow of investment and alliances with mature life sciences companies. This collaborative model has proven many times over to be an ideal framework to develop new treatments for patients.
Portfolio decisions for pharma pipelines are multifactorial, although patient need perhaps does not get the attention it merits. Rather, the gravitational pull around risk, investment return, and regulatory incentive tilts the pharma pipeline toward overconcentration in hot therapy areas.
With a declining share of global R&D and investment, Europe risks the pharmaceutical industry being increasingly molded in the image of others.
Investors at the Advanced Therapies Europe conference in London struck a bullish note on the state of the market and offered up advice for cell and gene developers from fundraising, platform development to manufacturing.